采用 SELDI-TOF 技术对石棉肺患者进行蛋白质组学检测，发现了血清蛋白生物标志物。
Proteomic detection of cancer in asbestosis patients using SELDI-TOF discovered serum protein biomarkers.
机构信息
Division of Allergy and Clinical Immunology, University of Colorado Denver, Aurora, CO 80045, USA.
出版信息
Biomarkers. 2011 Mar;16(2):181-91. doi: 10.3109/1354750X.2010.543289. Epub 2011 Jan 14.
OBJECTIVES
To identify biomarkers for cancer in asbestosis patients.
METHODS
SELDI-TOF and CART were used to identify serum biomarker profiles in 35 asbestosis patients who subsequently developed cancer and 35 did not develop cancer.
RESULTS
Three polypeptide peaks (5707.01, 6598.10, and 20,780.70 Da) could predict the development of cancer with 87% sensitivity and 70% specificity. The first two peaks were identified as KIF18A and KIF5A, respectively, and are part of the Kinesin Superfamily of proteins.
CONCLUSIONS
We identified two Kinesin proteins that can be potentially used as blood biomarkers to identify asbestosis patients at risk of developing lung cancer.
目的
鉴定石棉肺患者癌症相关的生物标志物。
方法
使用 SELDI-TOF 和 CART 技术，鉴定 35 例石棉肺患者（其中 35 例随后发生癌症，35 例未发生癌症）的血清生物标志物谱。
结果
3 个多肽峰（5707.01、6598.10 和 20780.70 Da）可预测癌症的发生，灵敏度为 87%，特异性为 70%。前两个峰分别被鉴定为 KIF18A 和 KIF5A，均属于驱动蛋白超家族蛋白。
结论
我们鉴定出两种驱动蛋白蛋白，它们可能作为血液生物标志物，用于识别有发展为肺癌风险的石棉肺患者。
Zotero 插件